73 related articles for article (PubMed ID: 26777972)
1. Cyclooxygenase-2 Expression in Non-Small Cell Lung Cancer Correlates With Hypertrophic Osteoarthropathy.
Rotas I; Cito G; Letovanec I; Christodoulou M; Perentes JY
Ann Thorac Surg; 2016 Feb; 101(2):e51-3. PubMed ID: 26777972
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2.
Kozak KR; Milne GL; Morrow JD; Cuiffo BP
Nat Clin Pract Rheumatol; 2006 Aug; 2(8):452-6; quiz following 456. PubMed ID: 16932737
[TBL] [Abstract][Full Text] [Related]
3. Hypertrophic pulmonary osteoarthropathy associated with non-small cell lung cancer demonstrated growth hormone-releasing hormone by immunohistochemical analysis.
Mito K; Maruyama R; Uenishi Y; Arita K; Kawano H; Kashima K; Nasu M
Intern Med; 2001 Jun; 40(6):532-5. PubMed ID: 11446681
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic syndrome of non-small cell lung carcinoma: a case with pancytopenia, leukocytoclastic vasculitis, and hypertrophic osteoarthropathy.
Cosar-Alas R; Yurut-Caloglu V; Karagol H; Caloglu M; Yalcin O; Turgut B; Saynak M; Uzal C
Lung Cancer; 2007 Jun; 56(3):455-8. PubMed ID: 17298855
[TBL] [Abstract][Full Text] [Related]
5. [A case of pulmonary pleomorphic carcinoma accompanied by pulmonary hypertrophic osteoarthropathy].
Ihara D; Hattori N; Yoshioka K; Fujitaka K; Kohno N
Nihon Kokyuki Gakkai Zasshi; 2011 Oct; 49(10):765-9. PubMed ID: 22117315
[TBL] [Abstract][Full Text] [Related]
6. [Hypertrophic pulmonary osteoarthropathy as a cue for NSCLC: four cases in the light of the current literature].
Lommatzsch M; Julius P; Lück W; Bier A; Virchow JC
Pneumologie; 2012 Feb; 66(2):67-73. PubMed ID: 22249782
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.
Hayashi M; Sekikawa A; Saijo A; Takada W; Yamawaki I; Ohkawa S
Anticancer Res; 2005; 25(3c):2435-8. PubMed ID: 16080471
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer containing growth hormone-releasing hormone associated with hypertrophic osteoarthropathy. Case report.
Nomori H; Kobayashi R; Kubo A; Morinaga S; Shintani Y; Sano T
Scand J Thorac Cardiovasc Surg; 1994; 28(3-4):149-52. PubMed ID: 7792560
[TBL] [Abstract][Full Text] [Related]
9. Hypertrophic osteoarthropathy as a clinical manifestation of lung cancer.
Davis MC; Sherry V
Clin J Oncol Nurs; 2011 Oct; 15(5):561-3. PubMed ID: 21951743
[TBL] [Abstract][Full Text] [Related]
10. More Than Knee Pain: A Case of Hypertrophic Osteoarthropathy Secondary to Lung Cancer.
Ong SK; Li X; Chen T
J Emerg Med; 2020 Nov; 59(5):e179-e181. PubMed ID: 32402481
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 upregulates β1 integrin expression via the E prostanoid 1 receptor/nuclear factor κ-light-chain-enhancer of activated B cells pathway in non-small-cell lung cancer cells.
Bai X; Yang Q; Shu W; Wang J; Zhang L; Ma J; Xia S; Zhang M; Cheng S; Wang Y; Leng J
Mol Med Rep; 2014 May; 9(5):1729-36. PubMed ID: 24584670
[TBL] [Abstract][Full Text] [Related]
12. Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells.
Kreutzer M; Fauti T; Kaddatz K; Seifart C; Neubauer A; Schweer H; Kömhoff M; Müller-Brüsselbach S; Müller R
Oncol Rep; 2007 Aug; 18(2):497-501. PubMed ID: 17611676
[TBL] [Abstract][Full Text] [Related]
13. [The principal rheumatologic paraneoplastic syndromes in cancer of the lung. Physiopathologico-clinical correlations and therapeutic approach].
Matucci Cerinic M; Di Lollo F
Clin Ter; 1985 Dec; 115(5):381-7. PubMed ID: 3913560
[No Abstract] [Full Text] [Related]
14. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer.
Murphey LJ; Williams MK; Sanchez SC; Byrne LM; Csiki I; Oates JA; Johnson DH; Morrow JD
Anal Biochem; 2004 Nov; 334(2):266-75. PubMed ID: 15494133
[TBL] [Abstract][Full Text] [Related]
15. [Expression of vascular endothelial growth factor C and cyclooxygenase-2 in non-small-cell lung carcinoma and their clinical significance].
Zhang HZ; Hua P; Li HG; Lü ZQ; Zeng YJ; Liu JG; Zeng H
Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):734-7. PubMed ID: 16483484
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
18. [Hypertrophic osteoarthropathy and lung cancer. Considerations on 2 cases].
Rodríguez García MS; Hernández Batuecas I; Pérez Arellano JL; Moreno de Vega y Lomo V; Núñez García J; Sánchez Sánchez R; González Villarón L
An Med Interna; 1988 Sep; 5(9):467-70. PubMed ID: 2856627
[No Abstract] [Full Text] [Related]
19. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer.
Ito T; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Nagai K; Miyazaki E; Kumamoto T; Nishiwaki Y
J Thorac Oncol; 2010 Jul; 5(7):976-80. PubMed ID: 20453688
[TBL] [Abstract][Full Text] [Related]
20. Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case report and review of the literature.
Birch E; Jenkins D; Noble S
BMJ Support Palliat Care; 2011 Sep; 1(2):189-92. PubMed ID: 24653233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
